A Phase 1/2 interventional study of AZD4512 and Surovatamig in B-cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca. Recruiting at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Lymphoma, B-Cell by AstraZeneca — 7 open to participants now, 9 under way, 3 of them phase 3. Lymphoma, B-Cell · AstraZeneca.
Among the 15 studies in Lymphoma, B-Cell by AstraZeneca, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 1/2, and was the 12th registered.
886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →7 of the 15 studies in Lymphoma, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Brazil and 9 more countries
Ages 65–130
AstraZeneca · Sites in Egypt, Iraq, Jordan and 7 more countries
AstraZeneca · Sites in United States, Australia, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
AstraZeneca
Ages 18–79
By country, each count listing its studies:
Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 3
First in 2007; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 164 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 226 across the 13 interventional studies, 516 across the 2 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
3 of the studies in Lymphoma, B-Cell by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT07882576AstraZenecaA Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma | 2027-01-30 |
| NCT07065344AstraZenecaA Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Lymphoma, B-Cell by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Study D9890C00001 (Lumi-NHL) is a modular study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-NHL. Module 1 aims to study AZD4512 monotherapy with participants in R/R B-NHL who have been exposed to at least 2 prior lines of therapy. Module 2 aims to study AZD4512 in combination with surovatamig in participants with relapsed or refractory LBCL.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Core Inclusion Criteria
Module 1 Monotherapy Inclusion criteria
Module 2 Surovatamig Combination Inclusion criteria
Core Exclusion Criteria
Module 1 Exclusion Criteria Patients are excluded if they have a diagnosis of post transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, CLL/SLL, Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma
Module 2 Exclusion Criteria
Participants will be excluded if they have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In module 1, the efficacy and safety of AZD4512 will be evaluated in R/R B-NHL. Module 1 will consist of both dose escalation and pharmacodynamic/safety backfills which will be used to support MTD and/or optimal biological dose (OBD) selection.
Drug: AZD4512
Module 2 aims to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of AZD4512 combined with surovatamig in participants with relapsed or refractory LBCL. The module will consist of both: dose escalation and pharmacodynamics/safety backfills.
Drug: AZD4512 · Drug: Surovatamig
AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
Surovatamig (AZD0486) is a 'bispecific' antibody to be administered via IV infusion
Percentage of participants with dose-limiting toxicities (DLTs) during the DLT period
To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 4 weeks
Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)
To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL
Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Frequency of SAEs/AEs leading to discontinuation of study treatment
To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL
Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters
To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL
Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Objective response rate (ORR)
ORR, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.
Time frame: Up to 2 years
Complete response (CR) rate
CR rate, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.
Time frame: Up to 2 years
Duration of response (DoR)
DoR, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.
Time frame: Up to 2 years
Progression-free survival (PFS)
PFS, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.
Time frame: Up to 2 years
Overall survival (OS)
OS, defined as the time from the date of first dose until date of death, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.
Time frame: Up to 2 years
Area Under plasma concentration-time Curve (AUC) of AZD4512, total antibody and total unconjugated warhead
To characterize the AUC of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Observed plasma (peak) drug concentration (Cmax) of AZD4512, total antibody and total unconjugated warhead
To characterize the Cmax of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Trough concentration (Ctrough) of AZD4512, total antibody and total unconjugated warhead
To characterize the Ctrough of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Half life of AZD4512, total antibody and total unconjugated warhead
To characterize the Half life of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Time to reach peak or maximum observed concentration (tmax) of AZD4512, total antibody and total unconjugated warhead
To characterize the Tmax of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Total clearance of AZD4512, total antibody and total unconjugated warhead
To characterize the Total clearance of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
The number and percentage of participants who develop anti-drug antibodies (ADAs)
To determine the immunogenicity of AZD4512 as monotherapy or in combination in participants with R/R B-NHL
Time frame: Up to 2 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.
Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 33 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Mar 2028 → Jul 2028 and completion Mar 2028 → Feb 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.